Revolution Medicines attracted takeover interest but decided to go it alone. This week’s FDA approval of its pancreatic cancer pill is the payoff. on.wsj.com/4y6GpBx
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: The Wall Street Journal (@wsj.com)
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: The Wall Street Journal (@wsj.com)